 |
Leader, Haematologic Malignancy Tumour Group, National University Cancer Institute, Singapore
Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore
Senior Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore |
A/Prof Chng obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. Fellowship training in haematology was completed in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics. His current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.
Education and Fellowships
MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS
Specialty Interests
-
Multiple Myeloma
-
Lymphoma
Awards and Honours
-
2011 - NUS Young Research Award
-
2010 - YLL SOM Faculty Outstanding Researcher Award (Young Researcher Category)
-
2009 - JCI The Outstanding Young Persons Award
-
2008 - NMRC Clinician Scientist Award
-
2007 - Celgene Future Leaders in Haematology Award
-
2007 - SMJ Best Reviewer Award 2006
-
2006 - 2007 Multiple Myeloma Research Foundation
-
2006 - Singapore Medical Journal Best Research Paper 2005 (Second Prize)
-
2004 - 2006 A*Star International Fellowship
-
2004 - Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation
-
2003 - Courage Star
-
2002 - Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation
Professional Memberships
-
American Society of Haematology
-
American Association of Cancer Research
-
International Myeloma Working Group
-
Asian Myeloma Network
-
Singapore Society of Haematology
Selected Publications
-
WJ Chng, SA Van Wier, G Ahmann, et al. A validated FISH Trisomy Index Demonstrates the Hyperdiploid and non-hyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156-2161. [IF – 10.56]
-
WJ Chng, G Ahmann, K Henderson, et al. Clinical implication of centrosome abnormalities in Plasma Cell Neoplasm. Blood 2006; 107: 3669-3675. [IF – 10.56]
-
WJ Chng, S Kumar, S Van Wier, et al. Molecular dissection of hyperdiploid myeloma using gene expression profiling. Cancer Res 2007; 67: 2982-2989. [IF – 7.54]
-
WJ Chng, E Braggio, R Valdez, G Mulligan, B Bryant, E Remstein, A Dogan, R Fonseca. The centrosome index is a powerful prognostic marker in multiple myeloma and identifies a cohort of patients that may benefit from aurora kinase inhibition. Blood 2008; 111: 1603-1609. [IF – 10.56]
-
WJ Chng, TH Chung, S Van Wier, et al. Correlation between Array-Comparative Genomic Hybridization Defined Genomic Gains and Losses and Survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24: 833-842. [IF – 8.30]
-
WJ Chng, GF Huang, TH Chung, et al. Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011 25 :1026-35 [IF – 8.30]
-
SB Ng, V Selvarajan, G Huang, J Zhou, AL Feldman, M Law, YL Kwong, N Shimizu, Y Kagami, K Aozasa, M Salto-Tellez, WJ Chng. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011; 223: 496-510.
-
J Zhou, C Bi, LL Cheong, S Mahara, SC Liu, KG Tay, TL Koh, Q Yu, WJ Chng. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011; 118: 2830-9. [IF – 10.56]
-
SB Ng, J Yan, G Huang, V Selvarajan, JL Tay, B Lin, C Bi, J Tan, YL Kwong, N Shimizu, K Aozasa, WJ Chng. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 201; 118: 4919-29. [IF – 10.56]
|
